Gel cuts inflammation and pain

Article

Loteprednol etabonate gel 0.5% is efficacious and safe for treating postoperative inflammation and pain caused by cataract surgery, claims a recent report.

Loteprednol etabonate gel 0.5% is efficacious and safe for treating postoperative inflammation and pain caused by cataract surgery, claims a recent report.

Dr Rajesh K. Raipal et al., See Clearly Vision Group, McLean, Virginia, USA, completed a prospective double-masked parallel-group study on 406 patients who underwent cataract surgery. Patients with anterior chamber cell (ACC) grade two or higher after surgery were randomized to receive loteprednol etabonate 0.5% gel or vehicle four times daily for 14 days.

Primary outcome measures included proportion of patients with complete resolution of ACC and no pain on postoperative day eight. The safety measures included adverse events, intraocular pressure (IOP), visual acuity, biomicroscopy and funduscopy findings and tolerability (ocular symptoms and drop comfort).

On day eight of the follow-up period 30.5% of the patients in the loteprednol group and 16.3% in the vehicle group had complete resolution of ACC, but the remainder had grade 0 pain.

Loteprednol etabonate was favoured as a method for complete resolution of ACC and grade 0 pain. One patient in each group experienced a significant increase in IOP but overall 85% of patients reported no discomfort on drop instillation.

The abstract was published in the latest edition of the Journal of Cataract and Refractive Surgery.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.